Risk for infection(s) from fiducial marker placement

Most of us who have gone through any form of image-guided external beam radiotherapy have had TRUS-guided transrectal placement of gold fiducial markers or radio transponders placed in our prostates. Some who have had salvage radiation have had them placed in the prostate bed. … READ MORE …

Can the “bone scan index” act as a surrogate marker for survival?

One of the problems with clinical trials for late-stage prostate cancer today is that we commonly need to follow all patients until death before we can collect sufficiently accurate data to be certain that a particular product is or is not effective in extending patient survival. … READ MORE …

Risks associated with implantation of “fiducial markers” before radiation therapy

It is becoming commonplace for men who are going to get external beam radiotherapy to treat their prostate cancer to have some form of “fiducial marker” (often tiny gold rods or balls) inserted into their prostates under transrectal ultrasound guidance to help ensure that the radiotherapy can be administered with the greatest possible accuracy. … READ MORE …

Who needs aggressive treatment after initial radiation … and who does not?

A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality. … READ MORE …

Prostasomes — another possible marker for prostate cancer aggression?

A story in Science Daily, based on new article in the Proceedings of the National Academy of Sciences (PNAS) , has suggested that blood levels of “prostasomes” may be a more accurate marker for prostate cancer risk that PSA levels in blood. … READ MORE …

Inflammation, biomarkers, and risk for prostate cancer

Whether there is any real association (let alone a cause and effect correlation) between clinically evident or subclinical inflammatory disorders and risk for prostate cancer is still not known — although long suspected. … READ MORE …

Is free, circulating DNA a useful marker for prostate cancer?

Elevated levels of free, circulating DNA (fcDNA) have previously been been found in the serum of prostate cancer patients compared with the levels in the serum of patients with benign prostate conditions. … READ MORE …

Cholesterol sulfate as a potential marker for prostate cancer

In a somewhat surprising series of studies, a team of researchers at Purdue University and the Indiana University School of Medicine have demonstrated that cholesterol sulfate has high potential as a marker for prostate cancer. … READ MORE …

Why Ki-67 may not be USEFUL in predicting aggressive prostate cancer

A paper to be presented on Sunday at the upcoming annual meeting of the American Association for Cancer Research suggests that “the proliferative index as assessed by Ki-67 immunoreactivity is an independent predictor of aggressive prostate cancer.” … READ MORE …

Is the TMPRSS2-ERG marker for prostate cancer clinically relevant?

We have long cautioned about whether the presence of apparent biologic “markers” in men with prostate cancer (“association”) is necessarily an implication that a specific marker really indicates anything clinically important. A paper published by a European team now helps to put this in perspective. … READ MORE …

Prostate cancer news reports: Wednesday, September 23, 2009

Today’s news reports cover items on:

  • Extent and number of biopsy cores and eligibility for active surveillance
  • Intermittent vs. complete androgen deprivation
  • Hormone therapy and risk for cardiovascular disease and death
  • Surrogate markets for disease progression in men with CRPC … READ MORE …

The news report: Friday, April 24, 2009

In today’s news report we touch on papers that address:

  • Genome studies and identification of real genomic risk for prostate cancer
  • More on the potential of 5-ARIs in prevention of prostate cancer
  • Whether we really need more studies on selenium as a potential prostate cancer prevention agent
  • The evolving potential of targeted focal therapy … READ MORE …

The Saturday prostate cancer news: November 29, 2008

We have separately addressed a report on 10-year outcome data following (non-robotic) laparoscopic radical prostatectomy for localized prostate cancer. In today’s other reports we have addressed:

  • The potential of annexin A3 as a marker for early diagnosis of prostate cancer
  • The ability of PSAV and PSAD to predict risk for prostate cancer in men with one or more negative prostate biopsies
  • Estrogens, estrogen receptors, and prostate cancer development and progression
  • Differences between clinical and pathological Gleason scores and the impact on outcomes following surgery … READ MORE …